{'fraction_non_alphanumeric': 0.038461538461538464, 'fraction_numerical': 0.021739130434782608, 'mean_word_length': 4.782608695652174, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Utility of ProGRP determinations in cancer patients.

BACKGROUND
The aim of this study was to assess the utility of ProGRP determinations in patients with selected cancer localization, during and after therapy.


MATERIALS AND METHODS
The study involved a reference group and a population of lung, breast, ovarian, and prostate cancer patients. ProGRP was evaluated using two-step chemiluminescent microparticle immunoassay (CMIA) manufactured by Abbott Diagnostics, and Architect i2000 analyzer.


RESULTS
During follow-up of SCLC patients, an increased value for ProGRP was found in 51% and for NSE only in 25.5% of the patients, whereas in NSCLC patients, percentages with elevated ProGRP and CYFRA 21-1 were 8.6% and 55.7%, respectively. SCLC patients also had the highest AUC values for ProGRP. In other cancers, the frequency of elevated ProGRP results were as follows: 13.1%--in breast cancer patients, 19.6%--in ovarian cancer patients, and 15.1%--in prostate cancer patients.


CONCLUSIONS
The presented study revealed that ProGRP is a tumor marker of choice in SCLC, because of its high diagnostic specificity in relation to the reference group and to the group with other malignancies.